Phase 3 Clinical Trials With Primary Completion Dates in September 2016
This is a list of Phase 3 trials with primary completion dates in September 2016 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
| Symbol | Company | Primary Completion Date | Phase | NCT ID | Title |
|---|---|---|---|---|---|
| ACOR | Acorda Therapeutics, Inc. | 2016-09-01 | Phase 3 | NCT02271217 | A Study to Evaluate the Efficacy and Safety of Two Dose Strengths of Dalfampridine Extended Release Tablets for Treatment of Stable Walking Deficits in Post-Ischemic Stroke |
| ACRS | Aclaris Therapeutics, Inc. | 2016-09-01 | Phase 3 | NCT02667288 | An Open-Label Safety Study of A-101 Solution |
| ACRS | Aclaris Therapeutics, Inc. | 2016-09-01 | Phase 3 | NCT02667275 | A Randomized, Double-Blind, Vehicle-Controlled Study in Subjects With Seborrheic Keratosis |
| ACRS | Aclaris Therapeutics, Inc. | 2016-09-01 | Phase 3 | NCT02667236 | A Study of A-101 Solution 40% in Subjects With Seborrheic Keratosis. |
| ARRY | Array BioPharma Inc. | 2016-09-01 | Phase 3 | NCT01909453 | Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma |
| EARS | Auris Medical Holding AG | 2016-09-01 | Phase 3 | NCT02040194 | AM-101 in the Treatment of Acute Tinnitus 3 |
| FOLD | Amicus Therapeutics, Inc. | 2016-09-01 | Phase 3 | NCT02384460 | ESSENCE Study: Efficacy and Safety of SD-101 Cream in Patients With Epidermolysis Bullosa |
| INNL | Innocoll Holdings | 2016-09-01 | Phase 3 | NCT02447172 | Study of a Topical Gentamicin-Collagen Sponge Along With Systemic Antibiotic in Infected Diabetic Foot Ulcers |
| JAZZ | Jazz Pharmaceuticals plc | 2016-09-01 | Phase 3 | NCT02348606 | "Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in OSA" |
| JAZZ | Jazz Pharmaceuticals plc | 2016-09-01 | Phase 3 | NCT02348593 | "Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in Narcolepsy" |
| LXRX | Lexicon Pharmaceuticals, Inc. | 2016-09-01 | Phase 3 | NCT02421510 | Efficacy, Safety, and Tolerability Study of Sotagliflozin as Adjunct Therapy in Adult Patients With Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control With Insulin Therapy |
| LXRX | Lexicon Pharmaceuticals, Inc. | 2016-09-01 | Phase 3 | NCT02384941 | Efficacy, Safety, and Tolerability Study of Sotagliflozin as Adjunct Therapy in Adult Patients With Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control With Insulin Therapy |
| MYGN | Myriad Genetics, Inc. | 2016-09-01 | Phase 3 | NCT01874353 | Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy |
| NWBO | Northwest Biotherapeutics, Inc. | 2016-09-01 | Phase 3 | NCT00045968 | Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer |
| OCUL | Ocular Therapeutix, Inc. | 2016-09-01 | Phase 3 | NCT02736175 | Phase 3 Study Evaluating Safety and Efficacy of OTX-DP for Treatment of Ocular Inflammation and Pain After Cataract Surgery |
| RIGL | Rigel Pharmaceuticals, Inc. | 2016-09-01 | Phase 3 | NCT02076412 | A Efficacy and Safety Study of Fostamatinib in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP) |
| RMD | ResMed Inc. | 2016-09-01 | Phase 3 | NCT01335087 | Continuous Positive Airway Pressure (CPAP) in Patients With Acute Coronary Syndrome and Obstructive Sleep Apnea (OSA) |
| TARO | Taro Pharmaceutical Industries Ltd. | 2016-09-01 | Phase 3 | NCT02595073 | Clinical Study to Evaluate the Efficacy and Safety of DSXS With Atopic Dermatitis |